Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + 2141-V11
- Development stage
- Unknown
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravesical
01
Overview
Gemcitabine + 2141-V11 is an investigational combination therapy being evaluated for the treatment of non-muscle invasive bladder cancer (NMIBC), particularly in patients who are unresponsive to standard Bacillus Calmette-Guérin (BCG) therapy. The regimen consists of gemcitabine, a well-established nucleoside analog chemotherapy, and 2141-V11, a novel Fc-optimized anti-CD40 agonist monoclonal antibody developed at Memorial Sloan Kettering Cancer Center. 2141-V11 is specifically engineered to have enhanced binding affinity for the inhibitory Fc-gamma receptor FcγRIIB, which facilitates CD40 multimerization and potent activation of antigen-presenting cells, thereby stimulating a robust anti-tumor T-cell response. The combination is administered intravesically to provide localized treatment within the bladder while minimizing systemic toxicity.
- Other names
- anti-CD40 agonist antibody 2141-V11anti-CD-40 agonist antibody 2141-V11anti-CD 40 agonist antibody 2141-V11
02
Targets
FCGR2B (Fc gamma receptor IIB)CD40 (Cluster of differentiation 40 receptor)
Beyond the preview
Go deeper on gemcitabine + 2141-V11.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + 2141-V11.